TLIS — Talis Biomedical Cashflow Statement
0.000.00%
Last trade - 00:00- $15.93m
- -$54.41m
- $2.13m
- 45
- 32
- 74
- 48
Annual cashflow statement for Talis Biomedical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -27.5 | -91.1 | -192 | -113 | -62 |
| Depreciation | |||||
| Non-Cash Items | 1.78 | 4.29 | 10.3 | 11.7 | 11.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.64 | -0.951 | 8.82 | -7.69 | -3.42 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -24.3 | -87 | -171 | -100 | -53.2 |
| Capital Expenditures | -0.578 | -8.2 | -2.87 | -1.61 | -0.486 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.578 | -8.2 | -2.87 | -1.61 | -0.486 |
| Financing Cash Flow Items | — | -1.45 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 39.6 | 247 | 234 | 0.406 | 0.033 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 14.7 | 152 | 60.2 | -101 | -53.7 |